PAYS Stock Risk & Deep Value Analysis

Paysign Inc

Technology • Software - Infrastructure

DVR Score

8.9

out of 10

Hidden Gem

What You Need to Know About PAYS Stock

We analyzed Paysign Inc using our deep value framework. Sign in to see our full verdict and DVR Score.

We ran PAYS through our deep value framework — analyzing financial health, distress signals, competitive moat, and risk factors. Our risk assessment: Moderate. Here's what we found.

Updated May 23, 2026Run Fresh Analysis →

PAYS Risk Analysis & Red Flags

What Could Go Wrong

Paysign's accelerated growth, particularly in the Pharma segment (+81.9% YoY in Q1 2026), relies on continued client acquisition and program success. If a major pharma client unexpectedly terminates their program, or if new client wins slow, the company may fail to meet its 30-35% annual revenue growth guidance, leading to a significant re-evaluation by the market.

Risk Matrix

Overall

Moderate

Financial

Low

Market

Low

Competitive

Medium

Execution

Medium

Regulatory

Medium

Red Flags

  • Revenue concentration risk (while not explicitly detailed, strong pharma growth often implies dependence on a few key programs).

  • Lack of detailed insider activity or institutional ownership information in provided sources (suggests lower public visibility or interest compared to larger caps, though not a direct 'red flag' on company performance).

  • Market cap of $0.38B means liquidity can be lower and volatility higher compared to larger companies.

Upcoming Risk Events

  • 📅

    Loss of Major Pharma Client (FY2027): The termination of a top 3 pharma program client, leading to a >$10M decrease in annualized revenue and significant deceleration in the fastest-growing segment.

  • 📅

    New Regulatory Hurdles in Prepaid Programs (FY2027-2028): Introduction of new restrictive state or federal regulations on prepaid card programs that increases compliance costs by >$2M annually or limits program growth.

When to Reconsider

  • 🚪

    Exit if quarterly revenue growth drops below 20% YoY for two consecutive quarters.

  • 🚪

    Sell if Adjusted EBITDA margin falls below 30% for any quarter.

  • 🚪

    Exit if unrestricted cash falls below $10 million without a clear strategic reason (e.g., major acquisition).

Unlock PAYS Risk Analysis & Red Flags

Create a free account to see the full analysis

What Does Paysign Inc (PAYS) Do?

Market Cap

$354.44M

Sector

Technology

Industry

Software - Infrastructure

Employees

173

Paysign, Inc. provides prepaid card programs, comprehensive patient affordability offerings, digital banking services, and integrated payment processing services for businesses, consumers, and government institutions. It offers solutions for corporate rewards, prepaid gift cards, general-purpose reloadable debit cards, employee incentives, consumer rebates, donor compensation, clinical trials, healthcare reimbursement payments and pharmaceutical payment assistance, and demand deposit accounts accessible with a debit card. The company also operates a customer service center; and offers a communication suite, including a kiosk, mobile app, two-way SMS, text alerts, and cardholder web portal. It markets its prepaid card solutions under the Paysign brand. The company serves companies and municipalities that require payment solutions for rewards, rebates, payment assistance, and other payments to their customers, employees, agents, and others. Paysign, Inc. was founded in 2001 and is headquartered in Henderson, Nevada.

Visit Paysign Inc Website

Investment Thesis

If Paysign continues its accelerated pace of new client acquisition, particularly in its high-growth pharma affordability segment (evidenced by 80%+ YoY growth), and successfully leverages its Payments-as-a-Service platform into adjacent regulated niches, then it can achieve annualized revenue approaching $200M-$250M by FY2028 with sustained 35%+ EBITDA margins. This would justify a market cap of $1.0B-$1.5B (2.5-4x current) in the medium term, setting a clear trajectory toward the 10x target of $3.8B+ within 3-5 years, as the market re-rates it for consistent high-margin growth and expanding competitive moat.

Is PAYS Stock Undervalued?

Paysign Inc. has delivered an exceptionally strong Q1 2026, significantly accelerating its growth trajectory. Revenue surged 50.8% YoY, with the high-margin Pharma segment leading at 81.9% growth. Net income more than doubled, and Adjusted EBITDA grew 113.4% YoY, pushing margins to impressive levels (37.8% Adj. EBITDA margin). The company maintains a pristine balance sheet with zero bank debt and ample cash. This execution reinforces its competitive moat in specialized, regulated payment niches (pharma affordability, plasma payments). While 10x growth is ambitious for any small-cap, Paysign's current performance, clear strategic vision, and robust financial health provide a compelling pathway, particularly if accelerated pharma client acquisition and Payments-as-a-Service expansion continue. The material improvement in financial performance since the last analysis justifies a significant score increase, indicating a strong move towards realizing its multi-bagger potential.

Unlock the full AI analysis for PAYS

Get the complete DVR score, risk analysis, and more

📈

Unlock the full report

Create a free account to see the DVR score, risk flags, and AI analysis.

PAYS Price Targets & Strategy

12-Month Target

$10.00

Bull Case

$13.00

Bear Case

$5.50

Valuation Basis

39x forward P/E applied to estimated FY2026 diluted EPS of $0.256 (based on midpoint of $13-16M net income guidance and ~56.6M shares outstanding).

Entry Strategy

Consider dollar-cost averaging in the $6.00-$7.00 range. Look for dips towards prior support levels or the 50-day SMA, if available.

Exit Strategy

Take 30-50% profit at $10.00-$11.00; consider full exit if the fundamental growth narrative deteriorates, especially if quarterly revenue growth falls below 20% YoY for two consecutive quarters. Stop loss at $5.50.

Portfolio Allocation

5-8% for an aggressive growth portfolio, given the small-cap status and high growth potential.

Price Targets & Strategy

Sign up free to unlock price targets and entry/exit strategies

Is PAYS Financially Healthy?

Valuation

P/E Ratio

46.94

Forward P/E

59.40

EV/EBITDA

46.35

Price/Sales

4.72

Profitability

Gross Margin

59.39%

Operating Margin

8.98%

Net Margin

9.21%

Return on Equity

17.19%

Revenue Growth

40.50%

EPS

$0.13

Balance Sheet

Current Ratio

1.11

Quick Ratio

1.10

Debt/Equity

0.06

Total Debt

$2.72M

Cash & Equivalents

$11.75M

Other

Beta (Volatility)

0.72

Does PAYS Have a Competitive Moat?

Sign in to unlock

Moat Rating

🛡️ Narrow

Moat Trend

Expanding

Moat Sources

3 Identified

Switching CostsIntangible Assets (Proprietary technology, regulatory expertise, established client relationships)Efficient Scale (benefiting from scale in specialized processing)

The moat is durable due to the complexity and regulatory hurdles of operating in specialized payment processing. Clients in pharma and plasma industries require robust compliance and seamless integration, making switching providers costly and risky. Paysign's experience and established platform create a strong barrier to entry for new competitors.

Moat Erosion Risks

  • Significant changes in payment regulations that could reduce the value of Paysign's compliance expertise or increase operational costs.
  • A large, well-capitalized competitor building or acquiring a similar specialized platform with superior technology or aggressive pricing.

PAYS Competitive Moat Analysis

Sign up to see competitive advantages

PAYS Market Intelligence

Sentiment & Insider Activity

Social Sentiment

Neutral. Limited specific data provided; assume general market sentiment mirrors current performance but with retail engagement not explicitly tracked.

Institutional Sentiment

Neutral. Analyst coverage and recent upgrade/downgrade information is not available in the provided sources.

Insider Activity (Form 4)

Not available in provided sources. Assuming normal activity based on lack of negative reports.

Options Flow

Normal options activity. No specific unusual options activity was reported in the provided sources.

Earnings Intelligence

Next Earnings

Estimated late July/early August 2026

Surprise Probability

High

Historical Earnings Pattern

Not available in provided sources. Given the strong Q1 results, positive reaction is expected for continued beats.

Key Metrics to Watch

Pharma revenue growth (YoY)Overall Revenue growth (YoY)Adjusted EBITDA marginUpdates to FY2026 guidance

Competitive Position

Top Competitor

GLOBALPAY (GPN) - Broader payments, but competes on digital solutions. Or specialized niche players like MedData (not publicly traded)

Market Share Trend

Gaining. Evidenced by 50.8% YoY revenue growth and 81.9% YoY pharma segment growth, outpacing broader market trends.

Valuation vs Peers

Trading at a reasonable valuation (11.4x forward EV/EBITDA, 26x forward P/E) for its current 30-35% revenue growth guidance and 37.8% EBITDA margins, suggesting potential for multiple expansion if growth accelerates further or remains robust.

Competitive Advantages

  • Regulatory expertise and compliance in specialized payment programs (e.g., healthcare, plasma).
  • Scalable proprietary Payments-as-a-Service (PaaS) platform that supports high volume.
  • High switching costs for large enterprise clients in regulated industries.

Market Intelligence

Sign up free to unlock sentiment, earnings intel, and peer analysis

What Could Drive PAYS Stock Higher?

Near-Term (0-6 months)

  • Q2 2026 Earnings Report (Estimated late July/early Aug 2026): If pharma revenue growth remains above 70% YoY and Adjusted EBITDA margin exceeds 38%, it signals continued acceleration beyond current guidance.
  • New Major Pharma Program Announcement (Q2/Q3 2026): Securing a contract with a top-tier pharmaceutical client that adds >$5M in annualized revenue, validating market leadership and scalability.

Medium-Term (6-18 months)

  • Expansion of Payments-as-a-Service (PaaS) to New Regulated Industries (FY2027): Successful pilot and commercial launch in a new vertical (e.g., specialized insurance, government disbursements) contributing >10% of total revenue.
  • Strategic M&A for Market Share or Technology (FY2027): Acquisition of a smaller player or complementary technology that adds >$20M in annualized revenue and expands their market moat in existing or adjacent niches.

Long-Term (18+ months)

  • Dominance in Pharma Patient Affordability (FY2029-2031): Capturing >20% market share in the growing ~10-15B TAM for patient affordability solutions, leading to $300M+ in annual revenue and sustained 40%+ EBITDA margins.
  • Full Platform Utilization & Scalability (FY2029-2031): Achieving economies of scale through high-volume processing across its PaaS platform, leading to 50%+ Adjusted EBITDA margins on $500M+ revenue.

Catalysts & Growth Drivers

Sign up free to see growth catalysts

What's the Bull Case for PAYS?

  • Watch quarterly Pharma revenue growth: sustained growth above 70% YoY indicates strong client acquisition and program expansion.

  • Monitor Adjusted EBITDA margin: consistency above 35% signals operating leverage and pricing power.

  • Track announcement of new client wins: specific mention of new significant pharma or PaaS clients validates growth catalysts.

Bull Case Analysis

Sign up free to see the bull case

Competing with PAYS

See how Paysign Inc compares to related companies

CompanyMarket CapDVR ScoreP/ERevenueProfit MarginRev Growth

Paysign Inc

PAYS

$354.4M8.946.9$68.5M9.2%40.5%

Apple Inc

AAPL

$4.4T1.636.0$391.0B27.1%12.8%Compare →

Alphabet Inc

GOOGL

$4.5T1.027.937.9%17.4%Compare →

Microsoft Corp

MSFT

$3.2T0.525.6$281.7B39.3%17.9%Compare →

📊 Explore More Stock Analysis

Get comprehensive Deep Value Reports for thousands of stocks. Research risk, financial health, and investment potential with our AI-powered analysis.

How Paysign Inc Makes Money

Paysign Inc. operates as a financial technology company specializing in highly customized prepaid card programs and payment processing. Its primary revenue drivers come from providing patient affordability programs for pharmaceutical companies, which help patients access critical medications, and from offering payment solutions for plasma donation centers. Paysign leverages its proprietary Payments-as-a-Service (PaaS) platform to manage these programs, earning revenue through transaction fees, program management fees, and interchange income. Essentially, it helps businesses in regulated sectors efficiently disburse and manage payments, acting as a compliant and scalable intermediary.

Read Full Business Model Breakdown

FAQ

What is the DVR Score for Paysign Inc (PAYS)?

As of May 23, 2026, Paysign Inc has a DVR Score of 8.9 out of 10, placing it in the "Hidden Gem" category. This score is generated by our AI-powered deep value analysis framework that evaluates growth potential, financial health, competitive moat, and risk factors.

What is the market capitalization of Paysign Inc?

Paysign Inc's market capitalization is approximately $354.4M. The company operates in the Technology sector within the Software - Infrastructure industry.

What ticker symbol does Paysign Inc use?

PAYS is the ticker symbol for Paysign Inc. The company trades on the NCM.

What is the risk level for PAYS stock?

Our analysis rates Paysign Inc's overall risk as Moderate. This assessment considers execution risk, market risk, financial risk, competitive risk, and regulatory risk. For a full breakdown, see the risk analysis section above.

What is the P/E ratio of PAYS?

Paysign Inc currently has a price-to-earnings (P/E) ratio of 46.9. This is above the market average, suggesting the stock may be priced for high growth expectations.

Is Paysign Inc's revenue growing?

Paysign Inc has reported revenue growth of 40.5%. The company is showing strong top-line momentum.

Is PAYS stock profitable?

Paysign Inc has a profit margin of 9.2%. The company is profitable but margins are modest.

How often is the PAYS DVR analysis updated?

Our AI-powered analysis of Paysign Inc is refreshed regularly to incorporate the latest financial data, market conditions, and news. The most recent update was on May 23, 2026.

Important Disclaimer – Not Financial Advice

Deep Value Reports is an independent research platform for educational and informational purposes only. We are not financial advisors, investment advisors, or licensed professionals. The analysis, scores, and information provided on this page for PAYS (Paysign Inc) should not be construed as personalized investment advice, a recommendation to buy or sell any security, or an offer to provide investment advisory services.

All investments involve risk, including the potential loss of principal. Past performance does not guarantee future results. Always conduct your own research, consider your financial situation, and consult with a qualified financial advisor before making any investment decisions.

Navigated to PAYS Stock Risk & Deep Value Analysis